Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Flerie ABFRA:1NP1 39 EV-to-FCF is -37.88 as of Jul. 14, 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 335 Biotechnology companies, Flerie AB ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Flerie AB's Enterprise Value is €130.37 Mil.
Flerie AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-3.44 Mil. Therefore, Flerie AB's EV-to-FCF for today is -37.88.
The historical rank and industry rank for Flerie AB's EV-to-FCF or its related term are showing as below:
FRA:1NP1'
s EV-to-FCF Range Over the Past 10 Years
Min: -174.2 Med: -4.79 Max: 172.44
Current: -38.7
During the past 12 years, the highest EV-to-FCF of Flerie AB was 172.44. The lowest was -174.20. And the median was -4.79.
FRA:1NP1's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs FRA:1NP1: -38.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Flerie AB's share price for today is €1.81.
Flerie AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.859.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Flerie AB EV-to-FCF Related Terms
Flerie AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Flerie AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1NP1 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Flerie AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Flerie AB's EV-to-FCF falls into.
Flerie AB's current Enterprise Value is €130.37 Mil.
Flerie AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a EV-to-FCF of -37.88 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #999999 out of 335 companies in the Biotechnology industry.
Is Flerie AB's EV-to-FCF too high?
Flerie AB's current EV-to-FCF is -37.88. Based on the distribution chart, Flerie AB ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Flerie AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #999999 out of 335 companies for EV-to-FCF. This places Flerie AB in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current EV-to-FCF is -37.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current EV-to-FCF of -37.88. The current EV-to-FCF is -37.88. Flerie AB's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current EV-to-FCF is -37.88 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
39GF Score
Get the complete analysis for FRA:1NP1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
